Archive for January, 2014

(ENTA) Results from Four All-Oral, Interferon-Free, Phase 3 Hep-C Studies

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) today announced results from the PEARL-II, PEARL-III, PEARL-IV and TURQUOISE-II studies. These studies are the remaining four phase 3 studies of the six phase 3 registrational studies being conducted by AbbVie for the treatment of genotype 1 (GT1) hepatitis C virus (HCV) infection using a regimen containing Enanta’s lead protease inhibitor ABT-450. ABT-450 is part of AbbVie’s investigational three direct-acting antiviral regimen consisting of boosted protease inhibitor ABT-450/ritonavir, NS5A inhibitor ABT-267, and non-nucleoside polymerase inhibitor ABT-333. These studies were conducted with and without ribavirin. The combination of the three different mechanisms of action in this regimen interrupts the HCV replication process with the goal of optimizing SVR rates across different patient populations.

Results from these studies demonstrate high sustained virologic response rates 12 weeks post treatment (SVR12) and tolerability in these GT1 patients and low rates of discontinuation due to adverse events.

A summary of AbbVie’s Phase 3 clinical trial results for the 3D regimen consisting of ABT-450/ritonavir, ABT-267 and ABT-333 follows:

Study Patient Type (number) Treatment Regimen Treatment
Duration
SVR12
PEARL-II GT1b treatment-experienced
(n=179)
  • 3D regimen (n=91)
12 week 100%
  • 3D regimen with ribavirin
    (n=88)
12 weeks 97%
PEARL-III GT1b, treatment-naïve
(n=419) 
  • 3D regimen (n=209)
12 weeks 99%
  • 3D regimen with ribavirin
    (n=210)
12 weeks 99%
PEARL-IV GT1a, treatment-naïve
(n=305) 
  • 3D regimen (n=205)
12 weeks 90%
  • 3D regimen with ribavirin
    (n=100)
12 weeks 97%
TURQUOISE-II GT1 treatment-naïve and treatment-
experienced with compensated
cirrhosis (n=380)
  • 3D regimen with ribavirin
    (n=208)
12 weeks 92%
  • 3D regimen with ribavirin
    (n=172)
24 weeks 96%
SAPPHIRE-I GT1 treatment-naïve
(n=631)
  • 3D regimen with ribavirin
    (n=473)
12 weeks 96%
SAPPHIRE-II GT1 treatment-experienced
(n=394)
  • 3D regimen with ribavirin
    (n=297)
12 weeks 96%

Overall, across the four studies, the three direct-acting antiviral regimen was well tolerated with few adverse event-related discontinuations. The most commonly reported adverse events in PEARL-II and PEARL-III were fatigue and headache. In PEARL-IV and TURQUOISE-II, the most commonly reported adverse events were fatigue, headache and nausea.

“We are pleased that SVR rates continue to be high in both treatment-naive and treatment-experienced GT1 HCV patients with and without ribavirin, as well as in the difficult-to-treat compensated cirrhotic patients. In addition, these trials demonstrate the exceptional tolerability of the regimen, with less than one percent (0.8%) of patients discontinuing therapy due to adverse events,” said Jay R. Luly, Ph.D. President and CEO. “We are also pleased that AbbVie has announced it is on track to begin major regulatory submissions early in the second quarter of 2014.”

These six phase 3 trials included 2,308 patients from more than 25 countries around the world. This is the only registrational program to include a dedicated study of an all-oral regimen in patients with compensated cirrhosis. In May 2013, AbbVie’s three direct-acting antiviral regimen with and without ribavirin for GT1 HCV was designated as a Breakthrough Therapy by the U.S. Food and Drug Administration (FDA). AbbVie has stated that it intends to disclose detailed study results at future scientific congresses and in publications.

About Study M13-389 (PEARL-II)

PEARL-II is a global, multi-center, randomized, open-label, controlled study to evaluate the efficacy and safety of 12 weeks of treatment with the three direct-acting antiviral regimen with and without ribavirin in non-cirrhotic, GT1b HCV-infected, treatment-experienced adult patients.

The study population consisted of 179 GT1b treatment-experienced patients with no evidence of liver cirrhosis: 91 patients were randomized to the regimen without ribavirin for 12 weeks, and 88 patients were randomized to the regimen plus ribavirin for 12 weeks. In the ribavirin-free arm, 100 percent (n=91/91) of patients achieved SVR12, while 97 percent (n=85/88) achieved SVR12 in the ribavirin-containing arm.

The most commonly reported adverse events were fatigue and headache. Discontinuations due to adverse events were reported in none of the patients in the ribavirin-free arm and two (2 percent) patients in the ribavirin-containing arm. There were no patients in either arm of the study that experienced virologic relapse or breakthrough.

About Study M13-961 (PEARL-III)

PEARL-III is a global, multi-center, randomized, double-blind, controlled study to evaluate the efficacy and safety of 12 weeks of treatment with the three direct-acting antiviral regimen with and without ribavirin in non-cirrhotic, GT1b HCV-infected, treatment-naïve adult patients.

The study population consisted of 419 GT1b treatment-naïve patients with no evidence of liver cirrhosis; 209 patients were randomized to the regimen without ribavirin for 12 weeks, and 210 patients were randomized to the regimen plus ribavirin for 12 weeks. Following 12 weeks of treatment, 99 percent receiving the regimen without ribavirin (n=207/209) and 99 percent receiving the regimen plus ribavirin (n=209/210) achieved SVR12.

The most commonly reported adverse events were fatigue and headache. No patient discontinued study drug due to adverse events. Virologic relapse or breakthrough was noted in none of the patients receiving the regimen without ribavirin and 0.5 percent of patients receiving the regimen plus ribavirin.

About Study M14-002 (PEARL-IV)

PEARL-IV is a global, multi-center, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of 12 weeks of treatment with the three direct-acting antiviral regimen with and without ribavirin in non-cirrhotic, GT1a HCV-infected, treatment-naïve adult patients.

The study population consisted of 305 GT1a treatment-naïve patients with no evidence of liver cirrhosis; 205 patients were randomized to the regimen without ribavirin for 12 weeks, and 100 patients were randomized to the regimen with ribavirin for 12 weeks. Following 12 weeks of treatment, 90 percent of patients receiving the regimen without ribavirin (n=185/205) and 97 percent receiving the regimen plus ribavirin (n=97/100) achieved SVR12.

The most commonly reported adverse events were fatigue, headache and nausea. Discontinuations due to adverse events were reported in two (1 percent) patients receiving the regimen without ribavirin and no patients in the ribavirin-containing arm. Virologic relapse or breakthrough was noted in 8 percent of patients receiving the regimen without ribavirin and 2 percent of patients receiving the regimen with ribavirin.

About Study M13-099 (TURQUOISE-II)

TURQUOISE-II is the first phase III study completed exclusively in GT1 cirrhotic patients investigating an all-oral interferon-free regimen. It is a global, multi-center, randomized, open-label study evaluating the efficacy and safety of 12 or 24 weeks of treatment with the three direct-acting antiviral regimen with ribavirin in cirrhotic, GT1a and GT1b HCV-infected, treatment-naïve and treatment-experienced adult patients.

The study population consisted of 380 GT1a and GT1b, treatment-naïve and treatment-experienced patients with compensated cirrhosis; 208 patients were randomized to the regimen plus ribavirin for 12 weeks, and 172 patients were randomized to the regimen plus ribavirin for 24 weeks. Following 12 weeks of treatment, 92 percent of patients (n=191/208) achieved SVR12. Following 24 weeks of treatment, 96 percent of patients (n=165/172) achieved SVR12.

The most commonly reported adverse events were fatigue, headache and nausea. Discontinuations due to adverse events were reported in four (2 percent) patients receiving the regimen with ribavirin for 12 weeks and four (2 percent) patients in the 24-week arm. Virologic relapse or breakthrough was noted in 6 percent of patients in the 12-week arm and 2 percent in the 24-week arm.

Additional information about AbbVie’s phase 3 studies can be found on www.clinicaltrials.gov.

Protease Inhibitor Collaboration with AbbVie (formerly the research-based pharmaceutical business of Abbott Laboratories)

In December 2006, Enanta and Abbott announced a worldwide agreement to collaborate on the discovery, development and commercialization of HCV NS3 and NS3/4A protease inhibitors and HCV protease inhibitor-containing drug combinations. ABT-450 is a protease inhibitor identified as a lead compound through the collaboration. Under the agreement, AbbVie is responsible for all development and commercialization activities for ABT-450. Enanta received $57 million in connection with signing the collaboration agreement, has received $55 million in subsequent clinical milestone payments, and is eligible to receive an additional $195 million in payments for regulatory milestones, as well as double-digit royalties worldwide on any revenue allocable to the collaboration’s protease inhibitors. Also, for any additional collaborative HCV protease inhibitor product candidate developed under the agreement, Enanta holds an option to modify the U.S. portion of it rights to receive milestone payments and worldwide royalties. With this option, Enanta can fund 40 percent of U.S. development costs and U.S. commercialization efforts (sales and promotion costs) for the additional protease inhibitor in exchange for 40 percent of any U.S. profits ultimately achieved after regulatory approval, instead of receiving payments for U.S. commercial regulatory approval milestones and royalties on U.S. sales of that protease inhibitor.

About Hepatitis C Virus (HCV)

Hepatitis C is a liver disease affecting over 170 million people worldwide. The virus is typically spread through direct contact with the blood of an infected person. Hepatitis C increases a person’s risk of developing chronic liver disease, cirrhosis, liver cancer and death. Patients with compensated cirrhosis have a liver that is heavily scarred but that can still perform many important bodily functions with few or no symptoms. There is an acute need for new HCV therapies that are safer and more effective for many variants of the virus.

About Enanta

Enanta Pharmaceuticals is a research and development-focused biotechnology company that uses its robust chemistry-driven approach and drug discovery capabilities to create small molecule drugs in the infectious disease field. Enanta is discovering, and in some cases developing, novel inhibitors designed for use against the hepatitis C virus (HCV). These inhibitors include members of the direct acting antiviral (DAA) inhibitor classes – protease (partnered with AbbVie), NS5A (partnered with Novartis) and nucleotide polymerase – as well as a host-targeted antiviral (HTA) inhibitor class targeted against cyclophilin. Additionally, Enanta has created a new class of antibiotics, called Bicyclolides, for the treatment of multi-drug resistant bacteria, with a focus on developing an intravenous and oral treatment for hospital and community MRSA (methicillin-resistant Staphylococcus aureus) infections.

Forward Looking Statements Disclaimer

This press release contains forward-looking statements, including with respect to the clinical data and the planned regulatory submissions for the three direct-acting antiviral HCV treatment regimen containing ABT-450. Statements that are not historical facts are based on our management’s current expectations, estimates, forecasts and projections about our business and the industry in which we operate and our management’s beliefs and assumptions. The statements contained in this release are not guarantees of future performance and involve certain risks, uncertainties and assumptions, which are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed in such forward-looking statements. Important factors that may affect actual results include final results of ongoing clinical trials of the three direct-acting antiviral ABT-450-containing regimen, the development, regulatory and marketing efforts of AbbVie (our collaborator on ABT-450), clinical development of competitive product candidates, regulatory submissions by AbbVie and its competitors in HCV and regulatory actions affecting the three direct-acting antiviral ABT-450-containing regimen and competitive regimens. Enanta cautions investors not to place undue reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this release, and Enanta undertakes no obligation to update or revise these statements, except as may be required by law.

Friday, January 31st, 2014 Uncategorized Comments Off on (ENTA) Results from Four All-Oral, Interferon-Free, Phase 3 Hep-C Studies

(CYTR) Announces Pricing of Approximately $75 Million Public Offering of Common Stock

CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced the pricing of its previously announced underwritten public offering. CytRx is offering 11.5 million shares of common stock at a public offering price of $6.50 per share for gross proceeds of approximately $75 million, prior to deducting underwriting discounts and commissions and estimated offering expenses payable by CytRx.

CytRx intends to use the net proceeds of the offering to fund clinical trials of its drug candidate aldoxorubicin and for general corporate purposes, which may include working capital, capital expenditures, research and development and other commercial expenditures. CytRx has granted the underwriters a 30-day option to purchase up to an additional 1.725 million shares of common stock. The offering is expected to close on or about February 5, 2014, subject to satisfaction of customary closing conditions.

Jefferies LLC is the sole book-running manager for the offering. Oppenheimer & Co. Inc., Aegis Capital Corp. and H.C. Wainwright & Co., LLC are acting as co-lead managers for the offering.

CytRx is offering the shares described above pursuant to a shelf registration statement on Form S-3, including a base prospectus, that was previously filed with and has been declared effective by the Securities and Exchange Commission (SEC). The securities may be offered only by means of a prospectus. A preliminary prospectus supplement related to the offering was filed with the SEC on January 30, 2014 and a final prospectus supplement related to the offering will be filed with the SEC today. Copies of the final prospectus supplement and the accompanying prospectus, when available, may be obtained from Jefferies LLC, Equity Syndicate Prospectus Department, 520 Madison Avenue, 12th Floor, New York, NY 10022, by email at Prospectus_Department@Jefferies.com or by phone at 877-547-6340 or by accessing the SEC’s website at http://www.sec.gov.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities of CytRx Corporation, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About CytRx Corporation

CytRx Corporation is a biopharmaceutical research and development company specializing in oncology. CytRx currently is focused on the clinical development of aldoxorubicin (formerly known as INNO-206), its improved version of the widely used chemotherapeutic agent doxorubicin.

Forward-Looking Statements

This press release contains statements relating to the proposed offering that are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Such statements involve risks and uncertainties, such as market risks and the risk that the conditions to the closing of the offering will not be satisfied and other risks detailed in CytRx’s filings with the SEC. All forward-looking statements are based upon information available to CytRx on the date the statements are first published. CytRx undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Friday, January 31st, 2014 Uncategorized Comments Off on (CYTR) Announces Pricing of Approximately $75 Million Public Offering of Common Stock

(LIQT) Announces Milestone Order for Flat Sheet Membranes

BALLERUP, Denmark, Jan. 30, 2014 LiqTech International, Inc. (NYSE: LIQT) (“LiqTech”) is pleased to announce that after extensive and successful testing LiqTech has received a production order for flat sheet silicon carbide membranes from the Middle East.

Finn Helmer, CEO, stated, “This first real production order opens up what we believe will be a significant market opportunity.  Tests have shown that the flat sheet silicon carbide membrane is unmatched in the market for cleaning drinking water, waste water and pre-reverse osmosis (“Pre-RO”) desalination.  Testing is ongoing in 22 additional sites and we expect that our success in recording this particular order will result in significant additional orders from the other test sites.

Further, our initial results in sea water Pre-RO with our new flat sheet membranes has demonstrated a more energy efficient and reliable technology compared to conventional technologies and this is beginning to be accepted by the market. In due course, we will expand our marketing efforts to cover other large applications that can utilize LiqTech’s flat sheet silicon carbide membranes.”

The initial flat sheet silicon carbide membranes order is for 250 meter2 and is scheduled for delivery in March.

ABOUT LIQTECH INTERNATIONAL, INC.

LiqTech International, Inc., a Nevada corporation, is a clean technology company that for more than a decade has developed and provided state-of-the-art technologies for gas and liquid purification using ceramic silicon carbide filters, particularly highly specialized filters for the control of soot exhaust particles from diesel engines and for liquid filtration. It also manufactures ceramic silicon carbide kiln furniture. Using nanotechnology, LiqTech develops products using proprietary silicon carbide technology. LiqTech’s products are based on unique silicon carbide membranes which facilitate new applications and improve existing technologies. For more information, please visit www.liqtech.com.

Forward-Looking Statements
This press release contains “forward-looking statements.” Although the forward-looking statements in this release reflect the good faith judgment of management, forward-looking statements are inherently subject to known and unknown risks and uncertainties that may cause actual results to be materially different from those discussed in these forward-looking statements. Readers are urged to carefully review and consider the various disclosures made by us in the our reports filed with the Securities and Exchange Commission, including the risk factors that attempt to advise interested parties of the risks that may affect our business, financial condition, results of operation and cash flows. If one or more of these risks or uncertainties materialize, or if the underlying assumptions prove incorrect, our actual results may vary materially from those expected or projected. Readers are urged not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. We assume no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.

Thursday, January 30th, 2014 Uncategorized Comments Off on (LIQT) Announces Milestone Order for Flat Sheet Membranes

(MEIL) Announces Affiliation With Ontario Biodiesel Association

LAS VEGAS, NV–(Jan 30, 2014) – Methes Energies International Ltd. (NASDAQ: MEIL), a renewable energy company that offers an array of products and services to biodiesel fuel producers, is pleased to announce that Methes Energies Canada Inc. has joined, as a Founding Member, the Ontario Biodiesel Association (OBA) which promotes the production and use of biodiesel in the Province of Ontario, Canada.

OBA members have invested over $80 million in plant and equipment to produce biodiesel in the province. Beside environmental benefits, the biodiesel industry provides a direct and indirect positive economic impact on the province and its agricultural sector. In May 2013, the Honorable Charles Sousa, Ontario Minister of Finance, announced and committed through the government’s budget, a consultation process to develop a Biodiesel policy in Ontario. That process began in July 2013 and the creation of the Ontario Biodiesel Association demonstrates the industry’s commitment to the collective interests and concerns of the industry.

Paul Grenier, Executive Director for the Ontario Biodiesel Association said, “OBA’s strength is the unity of biodiesel producers, supporting Provincial policy development, to improve Ontario’s air quality by promoting increased use of Biodiesel. The OBA is working with the Ontario government, feedstock suppliers and other key stakeholders to the industry to reach this goal.”

Methes President Nicholas Ng said, “We are proud to be a founding member of the OBA and look forward to work together with other producers in the province. The timing of a mandate in Ontario could not be better and we are hoping for an early implementation as early as April 2014. Other provinces in Canada have strong mandates already in place including production incentives for biodiesel producers. Ontario is moving in the right direction and we are excited to be part of the process in helping the government drafting policies that will have a positive impact for all stakeholders.”

About Methes Energies International Ltd.

Methes Energies International Ltd. is a renewable energy company that offers a variety of products and services to biodiesel fuel producers. Methes also offers biodiesel processors that are unique, truly compact, fully automated state-of-the-art and continuous flow that can run on a wide variety of feedstocks. Methes markets and sells biodiesel fuel produced at its showcase production facility in Mississauga, Ontario, Canada and at its 13 MGY facility in Sombra, Ontario, to customers in the U.S. and Canada, as well as providing multiple biodiesel fuel solutions to its clientele. Among its services are selling commodities to its network of biodiesel producers, selling their biodiesel production and providing clients with proprietary software to operate and control their processors. Methes also remotely monitors the quality and characteristics of its clients’ production, upgrades and repairs their processors and advises clients on adjusting their processes to use varying feedstock to improve the quality of their biodiesel. For more information, please visit www.methes.com.

This press release contains forward-looking statements regarding future events and financial performance. In some cases, you can identify these statements by words such as “may,” “might,” “will,” “should,” “except,” “plan,” “intend,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” or “continue,” the negative of these terms and other comparable terminology. These statements involve a number of risks and uncertainties and are based on numerous assumptions involving judgments with respect to future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the Company’s control. There are or may be important factors that could cause our actual results to materially differ from our historical results or from any future results expressed or implied by such forward looking statements. These factors include, but are not limited to, those discussed under the section entitled “Risk Factors” in our Annual Report on Form 10-K for the year ended November 30, 2012, filed on February 25, 2013, as amended, which is available at the U.S. Securities and Exchange Commission website at www.sec.gov. The forward-looking statements in this press release are based upon management’s reasonable belief as of the date hereof. The Company undertakes no obligation to revise or update publicly any forward-looking statements for any reason.

Contacts:
Methes Energies International Ltd.
Michel G. Laporte
Chairman and CEO
702-932-9964

Thursday, January 30th, 2014 Uncategorized Comments Off on (MEIL) Announces Affiliation With Ontario Biodiesel Association

(MEEC) Announces Major Commercial Commitment for Mercury Emissions Control

WORTHINGTON, OH–(Jan 30, 2014) – Midwest Energy Emissions Corporation (OTCQB: MEEC) (“ME2C”) today announced that it has received firm commitments from a major U.S. power producer for multi-year, mercury pollution control for MATS compliance. The commitments are for a fleet of 9 generating units. ME2C estimates that revenues for this relationship will grow to roughly $30 million per year by 2016, the final MATS compliance year, with initial revenues beginning in 2014.

The U.S. Environmental Protection Agency’s (EPA) Mercury and Air Toxic Standards (MATS) rule requires that all coal- and oil-fired power plants in the U.S., larger than 25 mega-watts, must remove roughly 90% of mercury from their emissions beginning April 16, 2015. Some plants have been given extensions into 2016. ME2C employs patented technology that has been shown to achieve mercury removal levels compliant with MATS at a significantly lower cost and with less operational impact than currently used methods

CEO Alan Kelley stated, “This very significant win for our Company is the direct result of over 20 years of dedicated research and technology development in advanced mercury control solutions. We believe that our proprietary technology is truly the best in class, and this business commitment serves as validation of our belief.”

Kelley continued, “This is a significant milestone achievement for our team and shareholders, with anticipated annual revenues of over $30 million per year when the full fleet of this single power provider is under MATS compliance. We further believe that this is just the beginning of the adoption of our technology by others and expect to be making additional commercial announcements soon.”

About Midwest Energy Emissions Corp. (ME2C) Midwest Energy Emissions Corp. delivers cost effective mercury capture technologies to power plants and other large industrial coal-burning units in the United States and Canada. The Company’s proprietary technology allows customers to meet the new, highly restrictive standards the U.S. EPA has set for mercury emissions, in an effective and economical manner with the least disruption to their current equipment and on-going operations. For more information, please refer to the Company’s website at www.midwestemissions.com.

Safe Harbor Statement: With the exception of historical information contained in this press release, content herein may contain “forward looking statements” that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management’s current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. Matters that may cause actual results to differ materially from those in the forward-looking statements include, among other factors, the gain or loss of a major customer, change in environmental regulations, disruption in supply of materials, a significant change in general economic conditions in any of the regions where our customer utilities might experience significant changes in electric demand, a significant disruption in the supply of coal to our customer units, the loss of key management personnel, failure to obtain adequate working capital to execute the business plan and any major litigation regarding the Company. In addition, this release contains time-sensitive information that reflects management’s best analysis only as of the date of this release. The Company does not undertake any obligation to publicly update or revise any forward-looking statements to reflect future events, information or circumstances that arise after the date of this release. Further information concerning issues that could materially affect financial performance related to forward-looking statements contained in this release can be found in the Company’s periodic filings with the Securities and Exchange Commission.

CONTACT INFORMATION

Keith R. McGee
Director of Investor Relations
Midwest Energy Emissions Corp.
614-505-6115
kmcgee@midwestemissions.com

Thursday, January 30th, 2014 Uncategorized Comments Off on (MEEC) Announces Major Commercial Commitment for Mercury Emissions Control

(CYTR) Announces Proposed Public Offering of Common Stock

CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced its intention, subject to market and other conditions, to commence an underwritten public offering of its common stock. CytRx intends to use the net proceeds of the offering to fund clinical trials of its drug candidate aldoxorubicin and for general corporate purposes, which may include working capital, capital expenditures, research and development and other commercial expenditures. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Jefferies LLC is the sole book-running manager for the offering.

CytRx is offering the shares described above pursuant to a shelf registration statement on Form S-3, including a base prospectus, that was previously filed with and has been declared effective by the Securities and Exchange Commission (SEC). The securities may be offered only by means of a prospectus. A preliminary prospectus supplement relating to the proposed offering will be filed with the SEC. Copies of the preliminary prospectus supplement and the accompanying prospectus, when available, may be obtained from Jefferies LLC, Equity Syndicate Prospectus Department, 520 Madison Avenue, 12th Floor, New York, NY 10022, by email at Prospectus_Department@Jefferies.com or by phone at 877-547-6340 or by accessing the SEC’s website at http://www.sec.gov.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities of CytRx Corporation, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About CytRx Corporation

CytRx Corporation is a biopharmaceutical research and development company specializing in oncology. CytRx currently is focused on the clinical development of aldoxorubicin (formerly known as INNO-206), its improved version of the widely used chemotherapeutic agent doxorubicin.

Forward-Looking Statements

This press release contains statements relating to the proposed offering that are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, including with respect to the completion, timing and size of its proposed offering. Such statements involve risks and uncertainties, such as market risks and the risk that the conditions to the closing of the offering will not be satisfied and other risks detailed in CytRx’s filings with the SEC. All forward-looking statements are based upon information available to CytRx on the date the statements are first published. CytRx undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Thursday, January 30th, 2014 Uncategorized Comments Off on (CYTR) Announces Proposed Public Offering of Common Stock

(ATNM) MissionIR Exclusive Audio Interview With CEO Dr. Kaushik J. Dave

ATLANTA, GA–(Jan 30, 2014) – MissionIR today announces the online availability of its interview with Actinium Pharmaceuticals, Inc. (OTCQB: ATNM) president and Chief Executive Officer Dr. Kaushik J. Dave, a 25-year veteran with extensive biotech and pharmaceutical experience. The full audio interview is available at the following link: http://ATNM.MissionIR.com/interview.html.

Actinium is a biotech company leveraging modern science and its proprietary platform to develop and commercialize groundbreaking therapies for treatment in different types of cancer that currently do not have any approved treatment.

Iomab-B is the company’s lead program for bone marrow conditioning in patients with acute myeloid leukemia (AML) who do not have any curative treatment options. Iomab-B is poised to start a pivotal phase 3 study, backed by significant data from five completed phase 1 and phase 2 clinical trials.

“This program has the potential to disrupt the field of bone marrow transplant, and as a consequence, has attracted a significant amount of interest from the medical community,” Dr. Dave stated in the interview.

Actinium’s pipeline also includes Actimab-A, currently in phase 1/phase 2 clinical studies as a primary induction treatment of AML. The company’s business model is to leverage its expertise and strong partnerships with leading cancer institutions to further the development of these drug candidates.

Dr. Dave detailed his education and extensive background in the pharmaceutical industry and drug development, noting that his interest in joining Actinium stemmed from recognizing the company’s “significant unrealized potential for growth.” Dr. Dave also briefly touched on the blended expertise of the rest of Actinium’s leadership and board of directors.

“These folks, all of them, bring complementary skills… all of which make our team well-equipped to face challenges of a rapidly ascending biotech company,” he stated.

In 2013, Actinium achieved several important milestones, as explained by Dr. Dave in the interview, which have positioned the company to reach several key objectives in 2014, including:

  • Iomab-B poised to start phase 3
  • Interim phase 2 results for Actimab-A
  • Uplist to Nasdaq or NYSE exchange
  • Obtaining additional analyst coverage
  • Establish strategic collaborations

Wrapping up the interview, Dr. Dave explained Actinium position in the biotech industry, how it is raising awareness in the investment community, and the company’s recent private placement of approximately $6.6 million in gross proceeds, which is allocated toward achieving the company goals for the year.

About Actinium Pharmaceuticals, Inc.

Actinium Pharmaceuticals, Inc. is a New York-based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. Actinium’s targeted radiotherapy is based on its proprietary delivery platform for the therapeutic utilization of alpha-emitting actinium-225 and bismuth-213 and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies. The Company’s lead radiopharmaceutical Iomab™-B will be used in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. The Company is conducting a single, pivotal, multicenter Phase 3 clinical study of Iomab™-B in refractory and relapsed Acute Myeloid Leukemia (AML) patients over the age of 55 with a primary endpoint of durable complete remission. The company’s second program, Actimab-A, is continuing its clinical development in a Phase 1/2 trial for newly diagnosed AML patients over the age of 60 in a single-arm multicenter trial.

For additional information, please visit the Company’s corporate Website: www.ActiniumPharmaceuticals.com

This press release may contain “forward-looking statements.” Expressions of future goals and similar expressions reflecting something other than historical fact are intended to identify forward-looking statements, but are not the exclusive means of identifying such statements. These forward-looking statements may include, without limitation, statements about our market opportunity, strategies, competition, expected activities and expenditures as we pursue our business plan. Although we believe that the expectations reflected in any forward-looking statements are reasonable, we cannot predict the effect that market conditions, customer acceptance of products, regulatory issues, competitive factors, or other business circumstances and factors described in our filings with the Securities and Exchange Commission may have on our results. The company undertakes no obligation to revise or update any forward-looking statements in order to reflect events or circumstances that may arise after the date of this press release.

Actinium Pharmaceuticals
New York, NY
www.ActiniumPharmaceuticals.com
646-459-4201
CSohmer@ActiniumPharmaceuticals.com

Mission Investor Relations
Atlanta, Georgia
http://www.MissionIR.com
404-941-8975
Investors@MissionIR.com

Thursday, January 30th, 2014 Uncategorized Comments Off on (ATNM) MissionIR Exclusive Audio Interview With CEO Dr. Kaushik J. Dave

(DSCI) Closes $86 Million Underwritten Public Offering of Common Stock

Derma Sciences, Inc. (the “Company”) (Nasdaq: DSCI), a tissue regeneration company focused on advanced wound care, today announced the closing of an underwritten public offering of 7,500,000 shares of common stock at a price to the public of $11.50 per share, which includes the exercise of the underwriters’ option to purchase 978,261 shares of common stock to cover over-allotments. Piper Jaffray & Co. and Canaccord Genuity Inc. were joint bookrunning managers for the offering. Oppenheimer & Co. Inc. and Roth Capital Partners were financial advisors to the Company.

Total net proceeds to the Company were approximately $80.7 million after deducting the underwriting discount and estimated offering expenses. The Company expects to use the proceeds from the offering for the continued development of DSC127, for sales force expansion and for general corporate purposes.

“The proceeds from this offering bring us closer to achieving our goal to be the leading company in advanced wound care,” said Edward J. Quilty, chairman and chief executive officer of Derma Sciences. “With more than $100 million in cash on our balance sheet now, we will expand our sales organization to sell our portfolio of cutting-edge products including AmnioMatrix®, our novel human placental-derived tissue products, and continue our DSC127 Phase 3 trials for diabetic foot ulcer healing. In addition, these funds allow us the flexibility to bring in other advanced wound care products and companies, should we identify additional suitable candidates,” Mr. Quilty added.

The offering was made pursuant to a shelf registration statement that was previously filed with and declared effective by the Securities and Exchange Commission (SEC) and a registration statement filed with and declared effective by the SEC pursuant to Rule 462(b) promulgated under the Securities Act of 1933, as amended.

A final prospectus supplement and accompanying prospectus related to the offering was filed with the SEC on January 27, 2014. Electronic copies of the prospectus supplement and accompanying prospectus can be obtained through the website of the SEC at www.sec.gov. When available, copies of the prospectus supplement and accompanying prospectus relating to the offering can also be obtained by contacting Piper Jaffray & Co., by mail at 800 Nicollet Mall, Suite 800, Minneapolis, MN 55402, or by telephone at (800) 747-3924 or by contacting the Syndicate Department of Canaccord Genuity Inc., by mail at 99 High Street, 12th Floor, Boston, MA 02110, or by telephone at (800) 225-6201.

This news release does not constitute an offer to sell or a solicitation of an offer to buy the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. This offering may be made only by means of a prospectus supplement and accompanying base prospectus.

About Derma Sciences, Inc.

Derma Sciences is a medical technology company focused on three segments of the wound care marketplace: pharmaceutical wound care products; advanced wound care dressings to address chronic wounds including diabetic ulcers; and traditional dressings. The Company has begun its Phase 3 clinical trials in diabetic foot ulcer healing with DSC127, based on excellent Phase 2 data. During the third quarter of 2014 Derma Sciences expects to begin marketing AmnioMatrix®, a portfolio of two novel human placental-derived tissue products for wound healing. Its MEDIHONEY® product is the leading brand of honey-based dressings for the management of wounds and burns. The product has been shown in clinical studies to be effective in a variety of indications. TCC-EZ® is its gold-standard total contact casting system for diabetic foot ulcers. Other novel products introduced into the $14 billion global wound care market include XTRASORB® for better management of wound exudate, and BIOGUARD® for barrier protection against microbes and other contaminants.

For more information please visit www.dermasciences.com.

Forward-Looking Statements

Statements contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as “may,” “will,” “expect,” “believe,” “anticipate,” “intend,” “could,” “estimate” or “continue” are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company’s actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release or that are otherwise made by or on behalf of the Company. Factors that may affect the Company’s results include, but are not limited to, product demand, market acceptance, impact of competitive products and prices, product development, completion of an acquisition, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks. Additional factors that could cause or contribute to differences between the Company’s actual results and forward-looking statements include but are not limited to, those discussed in the Company’s filings with the U.S. Securities and Exchange Commission.

Wednesday, January 29th, 2014 Uncategorized Comments Off on (DSCI) Closes $86 Million Underwritten Public Offering of Common Stock

(CGIX) Launches Webinar Series On DNA-Based Cervical Cancer Diagnostic Test

RUTHERFORD, N.J., Jan. 29, 2014  — Cancer Genetics, Inc. (Nasdaq:CGIX) (“CGI” or the “Company”), an emerging leader in DNA-based diagnostics, is launching a webinar series to inform clinicians and pathologists of the value of its proprietary DNA-based test for cervical cancer, FHACT™, which is processed in the Company’s CLIA certified, clinical laboratory. The webinar series will begin on Friday, January 31, at 9:30 a.m. ET and will be available again on Thursday, February 6, at 9:30 a.m. ET.

CGI’s webinar series, “An introduction to FHACT™: the FISH-based HPV-Associated Cancer Test,” was designed by Jane Houldsworth, PhD, Vice President of R&D at CGI, to better inform clinicians and pathologists about the value of using FHACT™ to help in triaging women with low grade cytological abnormalities prior to colposcopy.

Dr. Houldsworth led the research study of FHACT™ at CGI in collaboration with the National Cancer Institute (NCI). Data from the study was published in the July 2013 issue of Gynecologic Oncology (http://dx.doi.org/10.1016/j.ygyno.2013.06.005) where the genetic regions assessed in FHACT™ were found to be associated with severity of cervical lesions.

“About 2 million women are referred each year in the U.S. to undergo colposcopy, based on abnormal cytology and HPV testing, and of these significantly less than half require additional medical follow-up for diagnosed precancerous and cancerous lesions. Thus, there is a need to identify with greater efficiency women who are at risk to have such medically actionable lesions prior to referral for colposcopy. FHACT™ has the potential to reduce the health-care burden associated with cervical cancer and requires no further sample from the patient,” commented Dr. Houldsworth. “The potential of FHACT™ to provide more accurate and earlier detection of HPV-associated cancers and pre-cancers can save valuable time in the testing process, while creating substantial cost savings for the healthcare system.”

Although approximately 90% of HPV infections will be cleared within 2 years, a minority of precancerous lesions will progress to a higher-grade lesion. Women diagnosed with LSIL (low-grade squamous intraepithelial lesions) have a marginally higher risk of progression, and current high-risk HPV testing does not provide additional benefit in risk assessment for cancer. It is in these clinical settings where the integration of additional genetic biomarkers in the triage process is needed to limit unnecessary colposcopies and excisional procedures and to identify those women with lesions that are at risk of progressing to a higher grade cervical cancer.

CGI’s non-invasive FHACT™ test provides genomic information directly from leftover liquid cytology and does not require additional office visits. By using a unique combination of four genetic biomarkers, the FHACT™ test increases the sensitivity of detection of cells that show genomic abnormalities.

To register for the webinar series, please visit: http://www.cgifhact.com/webinar/.

The webinar series will be hosted by CGI’s Associate Product Manager, Alexandra Arndt, BS, CG (ASCP). Registered attendees of the live webinars can participate in Q&A sessions with Ms. Arndt. For those unable to attend the live events, the webinar series will be available for on demand viewing.

About Cancer Genetics:

Cancer Genetics, Inc. is an emerging leader in DNA-based cancer diagnostics, servicing some of the most prestigious medical institutions in the world. Our tests target cancers that are difficult to diagnose and predict treatment outcomes. These cancers include hematological, urogenital and HPV-associated cancers. We also offer a comprehensive range of non-proprietary oncology-focused tests and laboratory services that provide critical genomic information to healthcare professionals, as well as biopharma and biotech companies. Our state-of-the-art reference lab is focused entirely on maintaining clinical excellence and is both CLIA certified and CAP accredited and has licensure from several states including New York State. We have established strong research collaborations with major cancer centers such as Memorial Sloan-Kettering, The Cleveland Clinic, Mayo Clinic and the National Cancer Institute. For further information, please see www.cancergenetics.com.

Forward Looking Statements:

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development and potential opportunities for Cancer Genetics, Inc. products and services, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to, statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates”) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, maintenance of intellectual property rights and other risks discussed in the Company’s Form 10-Q for the quarter ended September 30, 2013 and other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Cancer Genetics disclaims any obligation to update these forward-looking statements.

CONTACT: Investor Relations
         RedChip Companies, Inc.
         Jon Cunningham, 800-733-2447, ext. 107
         jon@redchip.com
Wednesday, January 29th, 2014 Uncategorized Comments Off on (CGIX) Launches Webinar Series On DNA-Based Cervical Cancer Diagnostic Test

(LIVE) Announced Forward Stock Split Leaves Short Positions Nervous

NEW YORK, NY–(Jan 29, 2014) – LiveDeal (NASDAQ: LIVE) recently announced it will be initiating a 3-for-1 forward stock split in early February, but ahead of the split, investors with short positions will be looking to cover before their position also splits into one 3 times larger than currently held. Late in Tuesday’s session, we may have seen the first shot at trying to create doubt in the minds of long investors at LiveDeal. Shares of the company’s stock began to pull back after an article written by someone disclosing he does, in fact, have a short position in the stock, appeared on the financial website Seeking Alpha.

Like most Seeking Alpha articles written by those short a particular stock, their concerns are never aired when the stock is priced lower; instead, investors are treated to a laundry list of negative topics after the writer has built a short position at much higher prices. And, then in an attempt to look like the savior, the article is published and the writer hopes to profit exponentially after the seed of doubt is planted.

This phenomenon serves two purposes when the company is about to conduct a forward stock split. It helps the writer enjoy a nice payday as the price pulls back on fear, and it allows the author to cover their position before having to do so with 3 times as many shares after the stock splits and potentially moves to higher prices again. Keep in mind a $1 increase after the split is equivalent to a $3 increase before the split, so the stakes are high for anyone short.

Stockholders will receive three shares of Common Stock for every one share of Common Stock owned on the record date of February 3, 2014. Those additional shares will be distributed at the close of business on February 11th, and the stock split will go into effect on NASDAQ when trading begins on February 12th.

LiveDeal was due a pull back, and there are likely many investors on the sidelines who are cheering for a much lower split price than the $20-25 range it was trading at prior to Tuesday. Any pull back before the split means the stock will have a more attractive entry price after the split, thus ensuring more investors can afford the lower price, and grow with LiveDeal as its innovative new “instant-deal” platform takes off in more cities and in more industries outside of the dining industry.

About Stock Market Media Group

SMMG is a full service IR firm specializing in Research and Content Development. It offers a platform for corporate stories to unfold through the media with Reports, Interviews and Articles. For more information and to read disclaimers and disclosures: www.stockmarketmediagroup.com.

This article is the opinion of SMMG and was written based upon publicly available information. LiveDeal hasn’t endorsed or compensated SMMG for this article.

Contact:
Stock Market Media Group
Email Contact

Wednesday, January 29th, 2014 Uncategorized Comments Off on (LIVE) Announced Forward Stock Split Leaves Short Positions Nervous

(BSFT) Selected By Sprint BroadSoft to Deliver Next-Generation IMS and Voice Over LTE Services

BroadWorks to Power Sprint’s 3G IMS Network Transformation Vision and Migration to 4G Voice Over LTE

GAITHERSBURG, MD–(Jan 29, 2014) – BroadSoft, Inc. (NASDAQ: BSFT) today announced that Sprint (NYSE: S) has selected BroadSoft’s BroadWorks® platform to enhance VoIP services made available by Sprint to both its consumer and business customers.

BroadWorks, which is IR.92 and IR.94 compliant, is architected to easily integrate with 2G, 3G, and 4G IP Multimedia Subsystem (IMS)-based networks. BroadWorks’ Service Centralization and Continuity application server enables mobile network operators to deliver next-generation, Unified Communications (UC) services over their existing legacy GSM and/or CDMA networks. And with BroadWorks’ Voice Call Continuity, these UC services transition effortlessly from legacy networks as an operator migrates to VoLTE.

BroadSoft has extensive industry experience and superior capabilities, including:

  • Industry leadership with IMS networks, with over 70 deployments worldwide, and proven scalability to support millions of subscribers
  • A single architecture to serve both the consumer and business market segments, at a lower total cost of ownership through software-based media resource functions
  • Platform flexibility and support for industry standards, enabling the seamless integration of third-party technologies and applications
  • Virtualized and elastic software defined network architecture that integrates with other network components
  • Ability to deliver high-definition, Quality of Service mean opinion scores (MOS) required by mobile consumer subscribers

“We were seeking a single voice and video application server platform to support our IMS network transformation in order to provide the communication services both our consumer and enterprise customers are demanding today,” said Iyad Tarazi, Vice President of Network Development, Sprint.

Michael Tessler, president and chief executive officer, BroadSoft, said, “We are committed to providing superior technical capabilities that enable our service provider customers to offer the highest quality communications experience and look forward to helping Sprint achieve these objectives through our BroadWorks platform.”

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may be identified by their use of terms and phrases such as “enable” and other similar terms and phrases and include, among others, statements regarding the benefits to Sprint and its customers of using BroadSoft’s products and services. The outcome of the events described in these forward-looking statements is subject to known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from the results anticipated by these forward-looking statements, including, but not limited to, the financial and other benefits to BroadSoft resulting from the deployment of BroadSoft’s products and services by Sprint, as well as those factors contained in the “Risk Factors” sections of the Company’s Form 10-K for the year ended December 31, 2012, filed with the Securities and Exchange Commission, or SEC, on February 27, 2013, and in BroadSoft’s other filings with the SEC. All information in this release is as of January 29, 2014. Except as required by law, BroadSoft undertakes no obligation to update publicly any forward-looking statement made herein for any reason to conform the statement to actual results or changes in its expectations.

About BroadSoft

BroadSoft is the leading provider of software and services that enable mobile, fixed-line and cable service providers to offer Unified Communications over their Internet Protocol networks. The Company’s core communications platform enables the delivery of a range of enterprise and consumer calling, messaging and collaboration communication services, including private branch exchanges, video calling, text messaging and converged mobile and fixed-line services.

Wednesday, January 29th, 2014 Uncategorized Comments Off on (BSFT) Selected By Sprint BroadSoft to Deliver Next-Generation IMS and Voice Over LTE Services

(ONVO) Announces First Delivery of 3D Liver Tissue to Key Opinion Leader

SAN DIEGO, Jan. 29, 2014  — Organovo Holdings, Inc. (NYSE MKT: ONVO) (“Organovo”), a three-dimensional biology company focused on delivering breakthrough 3D bioprinting technology, today announced that it has performed its first 3D Liver tissue delivery.

The achievement marks the delivery of Organovo’s 3D Liver tissue to a laboratory outside of the company to a key opinion leader (KOL) for experimentation, and marks the achievement of a milestone along the pathway to commercial launch of its 3D liver tissue product.  Organovo achieved the milestone ahead of its April 2014 target date.  Key opinion leaders are generally experts, in this case top research scientists, in a particular field whose opinions and publications will influence practice.  Organovo expects KOLs to make recommendations on improvements to the tissue before launch and to influence peers through their reporting of their research results at conferences and through peer reviewed publications.

“This is an important milestone for Organovo R&D,” said Organovo Chief Technology Officer and Executive Vice President of Research and Development Dr. Sharon Presnell. “In developing these tissues, we have gone through a careful set of research studies involving many individual tissues, and greatly increased our ability to produce them.  By the end of January, we expect to have bioprinted nearly four hundred 3D Liver tissues during the month.”

Organovo also introduced updated guidance on the timing of its product launch.  Organovo had planned to launch its 3D Liver tissue product by the end of December 2014.  It now expects to commence the commercial launch and start generating revenue through a services model prior to December 2014.  “As pharmaceutical and biotechnology companies move to continue to outsource their R&D efforts,” explained Keith Murphy, Organovo’s chief executive officer, “our ability to deliver a service offering in addition to products will be critical to meet their needs and to enter the $7B preclinical research services market.”  The company anticipates that preclinical toxicology testing services can command prices in the high tens of thousands of dollars per compound for standard screening for liver alone.

Organovo’s 3D Liver tissues exhibit several key features that remain stable over time:

  • Tissue-like cellular density;
  • Multi-layered architecture with multiple cell types positioned relative to one another, reaching up to 500 microns thickness, with tissues comprised of up to 20 cell layers;
  • Albumin production 5-9 times greater than matched 2D controls, suggesting superior functionality;
  • Stable albumin production for over 40 days, fibrinogen and transferrin production, and inducible cytochrome P450 enzymatic activities, including CYP 1A2 and CYP 3A4;
  • Cholesterol biosynthesis, which has been demonstrated for the first time in a multi-cellular 3D human liver system in vitro;
  • Evidence of the formation of tight junctions in the liver tissues, demonstrated by cadherin and claudin staining by day 3 of tissue formation; and
  • Demonstration of appropriate response to hepatotoxic insults from acetaminophen, acetaminophen in combination with ethanol, and diclofenac.

Organovo plans to release additional data in 2014 on its 3D Kidney tissues and breast cancer tissues now in development.  In December, Organovo demonstrated that its NovoGen bioprinted breast cancer tissues retain compartmentalized structures with interaction between stromal and cancer cells, along with formation of endothelial networks and differentiation of adipocytes.  NovoGen 3D bioprinted constructs were demonstrated to be less susceptible to tamoxifen-induced toxicity than isolated 2D cancer cells when treated with the same dose of tamoxifen for the same duration, highlighting the potential utility of this model in identifying superior drugs with greater toxicity against complex, multicellular 3D tumor models.

Organovo also reminded investors of the continued availability of Organovo’s December 5, 2013 online presentation.  Organovo’s Chairman and Chief Executive Officer, Keith Murphy, presented in a live interactive online forum that was a recorded event.  The online content that can be accessed consists of a 30 min presentation as well as the text of a Q&A session that followed.

LINK: www.retailinvestorconferences.com > click on red “register / watch event now” button

The Company also reminded investors of its guidance to investors regarding “Short and Distort” articles.

About Organovo Holdings, Inc.
Organovo designs and creates functional, three-dimensional human tissues for medical research and therapeutic applications. The Company is collaborating with pharmaceutical and academic partners to develop human biological disease models in three dimensions. These 3D human tissues have the potential to accelerate the drug discovery process, enabling treatments to be developed faster and at lower cost. In addition to numerous scientific publications, the Company’s technology has been featured in The Wall Street Journal, Time Magazine, and The Economist. Organovo is changing the shape of medical research and practice. Learn more at www.organovo.com.

Safe Harbor State
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company’s products and technology; the timing of commercial launch and the market acceptance and potential for the Company’s products, and the risks related to the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our filings with the SEC, including the prospectus supplement that we filed with the SEC on November 27, 2013 and the transition report on Form 10-KT for the period ended March 31, 2013 that we filed with the SEC on May 24, 2013 and our other filings with the Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements, which speak only as of the date that they were made. These cautionary statements should be considered with any written or oral forward-looking statements that we may issue in the future. Except as required by applicable law, including the securities laws of the United States, we do not intend to update any of the forward-looking statements to conform these statements to reflect actual results, later events or circumstances or to reflect the occurrence of unanticipated events.

Wednesday, January 29th, 2014 Uncategorized Comments Off on (ONVO) Announces First Delivery of 3D Liver Tissue to Key Opinion Leader

(ASTC) Announces OEM Agreement

AUSTIN, Texas, Jan. 29, 2014  — 1st Detect Corporation, a subsidiary of Astrotech Corporation (Nasdaq:ASTC) announced today that the company has entered into a strategic OEM agreement with RIGAKU Corporation of Tokyo, Japan. The 1st Detect OEM-1000PI mass spectrometer has been integrated with RIGAKU’s Thermogravimetric Analyzer (TGA) to offer a higher performance, smaller and more cost effective solution than what is currently available in today’s world market.

1st Detect and RIGAKU have co-developed the successful integration of our respective technologies and have now completed the development of a highly capable and very competitively Thermogravimetric Analyzer. The integrated instrument named Thermo iMS2 is the world’s first integrated TGA with MS/MS capabilities and is expected to be well received by the international research and development markets.

“We are extremely pleased to be working with RIGAKU, a world recognized leader in chemical analysis instrumentation. This agreement marks a significant milestone in both our corporate progress and is a major endorsement of 1st Detect’s miniature mass spectrometer technology,” said Thomas B. Pickens III, Chairman and CEO of 1st Detect.

The OEM-1000PI, is a mass spectrometer component that is based on 1st Detect’s revolutionary MMS-1000™ instrument, and was customized to integrate RIGAKU’s stringent specifications including photo-ionization, atmospheric pressure sample introduction and a wider mass range than today’s state of the art cylindrical ion trap mass spectrometry.

“We are proud to have had the opportunity to leverage our expertise in miniature mass spectrometry to provide a world-class chemical analyzer to RIGAKU,” added David Rafferty, President & CTO of 1st Detect, “by integrating our breakthrough technologies, RIGAKU is able to offer a TGA system that provides more performance, in a smaller instrument, than the competition.”

1st Detect Corporation has developed an instrument that revolutionizes the chemical detection and analysis market by delivering lab performance mass spectrometry in a small, fast and affordable instrument. The 1st Detect mass spectrometer’s broad capabilities make it an ideal tool for a variety of applications in the research, security, industrial, process flow and healthcare markets; and is capable of detecting a wide variety of chemicals including residues and vapors from plastics and polymers.

About 1st Detect Corporation

1st Detect Corporation was formed by Astrotech Corporation (Nasdaq:ASTC) to develop and commercialize miniature mass spectrometer technology first developed under an agreement with NASA for use on the International Space Station. 1st Detect offers a breakthrough miniature mass spectrometer that fills an unmet need by being highly accurate, rapid, lightweight, and affordable.  For more information on 1st Detect Corporation, please visit www.1stDetect.com.

About Astrotech Corporation

Astrotech is one of the first space commerce companies and remains a strong entrepreneurial force in the aerospace industry. We are leaders in identifying, developing and marketing space technology for commercial use. Our Astrotech Space Operations business unit serves our government and commercial satellite and spacecraft customers with pre-launch services on the eastern and western range. 1st Detect Corporation has developed a breakthrough miniature mass spectrometer, while Astrogenetix, Inc. is a biotechnology company utilizing microgravity as a research platform for drug discovery and development.

This press release contains forward-looking statements that are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to risks, trends, and uncertainties that could cause actual results to be materially different from the forward-looking statement. These factors include, but are not limited to, continued government support and funding for key space programs, product performance and market acceptance of products and services, as well as other risk factors and business considerations described in the Company’s Securities and Exchange Commission filings including the annual report on Form 10-K. Any forward-looking statements in this document should be evaluated in light of these important risk factors. The Company assumes no obligation to update these forward-looking statements.

CONTACT: FOR MORE INFORMATION:
         Joshua Elbaum
         VP, Marketing
         +1 (512) 485-9530
         jelbaum@1stdetect.com
Wednesday, January 29th, 2014 Uncategorized Comments Off on (ASTC) Announces OEM Agreement

(ATNM) Engages Goodwin Biotechnology to Supply Iomab™-B for Its Phase 3 Clinical Study

Actinium Pharmaceuticals, Inc. (OTCQB:ATNM.OB) (“Actinium” or “the Company”), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced today that the Company entered into a manufacturing supply agreement with Goodwin Biotechnology, Inc. (“Goodwin”). According to the agreement, Goodwin will oversee the current Good Manufacturing Practices (cGMP) production of a monoclonal antibody anticipated to be used in an upcoming phase 3 clinical trial of Iomab™-B. Iomab™-B will be used in preparing patients for hematopoietic stem cell transplant (HSCT), commonly referred to as bone marrow transplant (BMT).

“This agreement with Goodwin represents a major risk mitigation step in conducting our phase 3 trial of Iomab™-B,” said Kaushik J. Dave, President and CEO of Actinium. “Goodwin has significant experience in working with companies like ours and the capabilities to provide the scale-up needed for a late-stage clinical trial. Goodwin’s competencies in process and product implementation, quality assurance, and GMP manufacturing make it ideally suited as a manufacturing partner for Actinium as we look forward to launching this pivotal phase 3 trial later this year.”

“We are very excited to be working with Actinium on Iomab™-B, their lead product candidate,” said Karl Pinto, CEO of Goodwin. “Actinium’s cutting edge proprietary platform is able to target different types of cancers that are without any approved treatment options. We look forward to a long-term partnership with Actinium, not only on Iomab™-B, but hopefully also on other products in their pipeline such as Actimab-A.”

About Goodwin Biotechnology, Inc.

Goodwin Biotechnology is a world-class CMO that offers a Single Source Solution™ through partnerships with clients for cell line development or exploratory proof of concept projects through process development and cGMP contract manufacturing of monoclonal antibodies, recombinant proteins, vaccines and Antibody Drug Conjugates (ADCs) for early and late stage clinical trials. By working with GBI, our clients can enhance the value of their product candidates with clear development and manufacturing strategies as well as a roadmap to meet the highest quality product requirements from the milligram and gram range to kilogram quantities as the product candidates move along the clinical approval pathway in a cost-effective, timely, and cGMP compliant manner to enhance patients’ lives. With over 20 years of experience as an independent contract manufacturer, GBI has worked as a strategic partner with companies of all sizes from small university spin-offs to major research institutes, government agencies and large, established and multi-national biopharmaceutical companies. Additional information may be found at www.GoodwinBio.com.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc. (ATNM.OB) is a New York-based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. Actinium’s targeted radiotherapy is based on its proprietary delivery platform for the therapeutic utilization of alpha-emitting actinium-225 and bismuth-213 and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies. The Company’s lead radiopharmaceutical Iomab™-B will be used in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. The Company is conducting a single, pivotal, multicenter Phase 3 clinical study of Iomab™-B in refractory and relapsed Acute Myeloid Leukemia (AML) patients over the age of 55 with a primary endpoint of durable complete remission. The company’s second program, Actimab-A, is continuing its clinical development in a Phase 1/2 trial for newly diagnosed AML patients over the age of 60 in a single-arm multicenter trial. For more information, please visit www.actiniumpharmaceuticals.com.

About Iomab™-B

Iomab™-B will be used in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant which is the fastest growing hospital procedure in the U.S. The Company established an agreement with the FDA that the path to a Biologics License Application (BLA) submission will include a single, pivotal Phase 3 clinical study if it is successful. The trial population in this two arm, randomized, controlled, multicenter trial will be refractory and relapsed Acute Myeloid Leukemia (AML) patients over the age of 55. The trial size was set at 150 patients with 75 patients per arm. The study design of the pivotal trial is based on results of an earlier Phase 1/2 trial in which sixty percent of the older patients with refractory and relapsed AML exhibited disease free survival estimated at six months. The primary endpoint in the pivotal Phase 3 trial is durable complete remission, defined as a complete remission lasting at least 6 months. There are currently no treatments approved by the FDA for AML in this patient population and there is no defined standard of care. Iomab™-B has completed several physician sponsored clinical trials examining its potential as a conditioning regimen prior to a bone marrow transplant in various blood cancers including the Phase 1/2 study in relapsed and/or refractory AML patients. The results of these studies in over 300 patients have demonstrated the potential of Iomab™-B to create a new treatment paradigm for bone marrow transplants by: expanding the pool to ineligible patients who do not have any viable treatment options currently; enabling a shorter and safer preparatory interval for HSCT; reducing post-transplant complications; and showing a clear survival benefit including curative potential.

Iomab™-B is a radioimmunoconjugate consisting of BC8, a novel murine monoclonal antibody, and iodine 131 radioisotope. BC8 has been developed by Fred Hutchinson Cancer Research Center to target CD45, a pan-leukocytic antigen widely expressed on white blood cells. This antigen makes BC8 potentially useful in targeting white blood cells in preparation for hematopoietic stem cell transplantation in a number of blood cancer indications, including acute myeloid leukemia (AML), chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), Hodgkin disease (HD), Non-Hodgkin lymphomas (NHL) and multiple myeloma (MM). When labeled with radioactive isotopes, BC8 carries radioactivity directly to the site of cancerous growth and bone marrow while avoiding effects of radiation on most healthy tissues.

For more information:

Visit our web site www.actiniumpharmaceuticals.com

Forward-Looking Statement for Actinium Pharmaceuticals, Inc.

This news release contains “forward-looking statements” as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management’s current expectations and involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

Wednesday, January 29th, 2014 Uncategorized Comments Off on (ATNM) Engages Goodwin Biotechnology to Supply Iomab™-B for Its Phase 3 Clinical Study

(IMMY) to Exhibit Pre-Commercial Ophthalmic Formulations

-Company Continues Go Dropless™ Information Campaign Targeted at Ophthalmologists-

SAN DIEGO, Jan. 28, 2014  — Imprimis Pharmaceuticals, Inc. (NASDAQ:IMMY), a specialty pharmaceutical company focused on the development and commercialization of proprietary sterile and topical drug formulations, today announced that it will be attending the ACES/SEE Caribbean Eye Meeting (http://caribbeaneyemeeting.com/) in Cancun, Mexico, January 31 to February 4, 2014. Imprimis will continue its Go Dropless™ campaign (http://dropless.com/), which has been created to inform ophthalmologists about dropless eye surgery and the injectable compounded drug formulations Imprimis has developed in conjunction with physicians and pharmacists.

Imprimis previously announced its plans to launch its proprietary ophthalmic sterile injectable compounded formulations during the first half of 2014. These therapies, designed for ophthalmic surgery patients, include a formulation combining triamcinolone acetonide and moxifloxacin hydrochloride. A similar combination adds the antibiotic vancomycin. Both of these drug formulations have been used by physicians during cataract surgeries and many other eye surgeries where there is inflammation and a chance for post-operative infection.  Imprimis anticipates also offering a suite of lyophilized mydriatic drug formulations using either epinephrine or phenyepherine, both of which may be combined with lidocaine.

The Caribbean Eye Meeting attendance continues the strong momentum Imprimis has been building from previous meetings, including the American Academy of Ophthalmology in New Orleans, Louisiana and “Cataract Surgery: Telling It Like It Is” in Sarasota, Florida. The company has also held several Ophthalmic Advisory Board meetings with national thought leaders. Each of these events provides the opportunity to build relationships and gain valuable insight on the company’s innovations and business model from the perspective of the cataract surgeons who participate.

For those interested in scheduling meetings with Imprimis at the ACES/SEE Caribbean Eye Meeting, please register at http://dropless.com/go-dropless/.

As the company previously stated when it acquired the intellectual property for these formulations in August 2013, the current treatment regimen for the prevention of post-cataract surgery complication is primarily a costly pre-operative and post-operative self-administered eye drop regimen, which requires strict patient compliance and careful adherence to a prescribed dosing schedule. Individuals with physical limitations, impaired manual dexterity, or those who lack a supportive care giver, are particularly vulnerable to non-compliance and the subsequent complications of untreated post-surgical issues.  Imprimis’ uniquely designed drug formulations utilize a fourth generation quinolone therapy combined with inflammatory suppression which provide new choices for physicians to address and resolve the primary ocular complications of ophthalmic surgery: infection risk and post-operative inflammation.

Imprimis believes that its formulations may have broad application in ophthalmic surgery, including the multi-billion global cataract surgery drug market.  The cataract surgery market continues to grow tremendously. According to Market Scope, nearly 22 million cataract surgeries were performed globally in 2013[1]. This growth is not only because of the expanding aging population, but because the age at which patients demand cataract surgery has lowered, shown in a study by Mayo Clinic[2], portending the ophthalmology drug market to reach $19.8 billion in 2014.[3]

ABOUT IMPRIMIS PHARMACEUTICALS
San Diego-based Imprimis Pharmaceuticals, Inc. (Nasdaq: IMMY) is a specialty pharmaceutical company focused on the development and commercialization of proprietary sterile and topical drug formulations. Imprimis’ patent-pending drug formulations are available today and are being prescribed by physicians. For more information, please visit www.imprimispharma.com or www.GoDropless.com.

SAFE HARBOR

This press release contains forward looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such “forward looking statements.” Forward looking statements are based on management’s current expectations and are subject to risks and uncertainties which may cause results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include Imprimis’ ability to acquire, develop, commercialize and market new formulations and technologies, enter into strategic alliances and transactions, including arrangements with pharmacies, physicians and healthcare organizations, commercialize its formulations and technologies, obtain intellectual property protection for its assets, accurately estimate its expenses and cash burn and raise additional funds, as well as the success of additional research and development activities related to its formulations and technologies, the projected size of the potential market for its technologies and formulations, unexpected new data, safety and technical issues, regulatory and market developments impacting compounding pharmacies, outsourcing facilities and the pharmaceutical industry, competition and market conditions. These and additional risks and uncertainties are more fully described in Imprimis’ filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Such documents may be read free of charge on the SEC’s web site at www.sec.gov. Undue reliance should not be placed on forward looking statements, which speak only as of the date they are made. Except as required by law, Imprimis undertakes no obligation to update any forward looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.

1. Market Scope 2013 Comprehensive Report on the Global Cataract Surgical Equipment Market

2. Increasing incidence of cataract surgery: Population-based study. Journal of Cataract & Refractive Surgery, 2013; 39 (9)

3. MarketsandMarkets, May 2010, Report Code PH1300

MEDIA CONTACT:  Jen Carroll
jcarroll@imprimispharma.com
858.704.4587

Tuesday, January 28th, 2014 Uncategorized Comments Off on (IMMY) to Exhibit Pre-Commercial Ophthalmic Formulations

(SANM) Announces Appointment of New Chief Operating Officer

Contec Holdings, LTD, (“Contec” or the “Company”) the market leader in repair and refurbishment services business, today announced the appointment of Jyoti (JK) Kapoor as its Chief Operating Officer. Mr. Kapoor will assume this role effective immediately.

“We are delighted to have Mr. Kapoor join the Contec team” said Hari Pillai, President and Chief Executive Officer of Contec. “Mr. Kapoor’s outstanding operations experience gained over multiple international and U.S. assignments with leading edge technology companies, combined with his proven track record of scaling organizations in growth environments is perfectly matched to Contec’s needs as we embark on a period of rapid expansion and growth.”

“I am very pleased to join the Contec team,” said Mr. Kapoor. “Contec’s strong positive reputation with its blue-chip customers is indicative of the quality, cohesion and performance of the organization. I particularly like the detailed roadmap for accelerated investment and growth that leverages the experience and strength of the management team. I’m really looking forward to contributing to the success of the organization and unlocking the company’s enormous potential” added Mr. Kapoor.

Prior to joining Contec, Mr. Kapoor served as Global Vice President of Operations at ABB (NYSE:ABB) where he led photovoltaic inverter manufacturing operations and spearheaded dramatic improvements in customer satisfaction, profitability, working capital and product quality. Prior to that, Mr. Kapoor served in a number of Operations Management roles at Sanmina-SCI (NASDAQ:SANM), the California-based design and manufacturing services company and Iomega (NYSE:IOM), a global leader in data storage products for consumers and business enterprises. Mr. Kapoor holds an MBA in Operations Management from Thunderbird School of Global Management, Arizona and Bachelors in Chemical Engineering from MIT, India.

About Contec

Leveraging 35 years of experience in the cable industry and its industry leading test solutions such as QuickTest®, Contec is the market leader in the test, repair and refurbishment of customer premise equipment for the world’s leading cable, satellite and IP-based Multiple-System Operators (MSO’s). More recently, the company has expanded its services to include repair and refurbishment of a wide array of electronics hardware products. With an expanding network of service centers around the world, Contec is headquartered in Schenectady, New York. Learn more at www.gocontec.com.

Tuesday, January 28th, 2014 Uncategorized Comments Off on (SANM) Announces Appointment of New Chief Operating Officer

(YRCW) TNFINC Certifies Ratification of Worldwide Contract Terms

OVERLAND PARK, Kan., Jan. 28, 2014  — YRC Worldwide Inc. (Nasdaq:YRCW) announced today that the Teamsters National Freight Industry Negotiating Committee (TNFINC) certified the results of the Teamsters ratification vote and that, on a related note, the certified Amended Memorandum of Understanding (MOU) satisfied the relevant condition of the equity transaction announced on December 23rd.

“The ratification of the revised MOU, our improved performance and the committed equity transaction clear the way for us to enter the senior debt markets to refinance our current term and asset-based loans,” said Jamie Pierson, chief financial officer of YRC Worldwide.

As previously announced on December 23, 2013, the company has entered into agreements whereby the company would issue $250 million of common stock and preferred stock and use the proceeds to pay off its existing 6% Convertible Notes due February 2014 and defease and/or pay off its existing Series A Convertible Notes due March 2015. In addition, holders of approximately $50 million in principal amount of the company’s existing Series B Convertible Notes due March 2015 have agreed to exchange or convert those notes to common stock, further reducing the company’s debt. The investors have confirmed that the revised MOU is satisfactory under the terms of these existing agreements.

The company plans to hold a bank meeting on Tuesday, January 28, 2014, at 2:00pm EST to launch the new senior credit facilities.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The words “will,” “would,” “anticipate,” “expect,” “believe,” “intend” and similar expressions are intended to identify forward-looking statements. It is important to note that actual efficiencies from the new agreement, results of the contingencies to obtaining the efficiencies, closing of the proposed equity transaction discussed in this news release, our ability to restructure our pension fund debt and refinance our senior debt, and the overall results of our refinancing strategy, including the amount our existing stockholders will be diluted, will be determined by a number of factors, including (among others) those risk factors that are from time to time included in the company’s reports filed with the SEC, including the company’s reports on Forms 10-K and 10-Q and the company’s Current Report on Form 8-K filed on December 9, 2013.  Further, the company cannot provide you with any assurances that the efficiencies will be achieved, that the conditions contained in the definitive agreements related to the proposed equity transaction will be satisfied or that the proposed equity transaction, the pension fund debt restructuring or the senior debt refinancing can be completed in the timeframes required under the company’s various agreements with its stakeholders, if at all.  In addition, even if all the contemplated transactions are completed, the company’s future results could differ materially from any results projected in such forward-looking statements because of a number of factors, including (among others) the risk factors that are from time to time included in the company’s aforementioned reports.

About YRC Worldwide

YRC Worldwide Inc., a Fortune 500 company headquartered in Overland Park, Kan., is the holding company for a portfolio of successful companies including YRC Freight, YRC Reimer, Holland, Reddaway, and New Penn. YRC Worldwide has one of the largest, most comprehensive less-than-truckload (LTL) networks in North America with local, regional, national and international capabilities. Through its team of experienced service professionals, YRC Worldwide offers industry-leading expertise in heavyweight shipments and flexible supply chain solutions, ensuring customers can ship industrial, commercial and retail goods with confidence. Please visit www.yrcw.com for more information.

Follow YRC Worldwide on Twitter: http://twitter.com/yrcworldwide

CONTACT: Investor Contact:
         Stephanie Fisher
         913-696-6108
         investor@yrcw.com

         Media Contact:
         Suzanne Dawson
         LAK Public Relations, Inc.
         212-329-1420
         sdawson@lakpr.com
Tuesday, January 28th, 2014 Uncategorized Comments Off on (YRCW) TNFINC Certifies Ratification of Worldwide Contract Terms

(ALIM) Announces $37.5 Million Private Placement

ATLANTA, Jan. 28, 2014  — Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that it has obtained commitments from certain non-affiliated institutional investors to purchase approximately $37.5 million of its common stock in a private placement. Proceeds from the private placement are expected to be used for general corporate and working capital purposes.

“This financing will provide us with working capital to support our continued commercialization of ILUVIEN® in Europe and the ongoing pursuit of FDA approval in the United States,” said Dan Myers, president and chief executive officer of Alimera.

Alimera has entered into a securities purchase agreement with the investors pursuant to which Alimera will sell an aggregate of 6,250,000 shares of its common stock at a purchase price of $6.00 per share. The private placement is subject to customary closing conditions and is expected to close during the week of January 27, 2014.

Cowen and Company, LLC served as sole placement agent for the transaction.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities of Alimera nor shall there be any sale of securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

The common stock offered in the private placement has not been registered under the Securities Act of 1933, as amended, or state securities laws, and may not be offered or sold in the United States without being registered with the Securities and Exchange Commission (SEC) or through an applicable exemption from SEC registration requirements. The shares of common stock were offered only to accredited investors. Alimera has agreed to file a registration statement with the SEC covering the common stock purchased by the investors. Any offering of Alimera’s securities under the resale registration statement will be made only by means of a prospectus.

About Alimera Sciences, Inc.

Alimera Sciences, Inc., headquartered in Alpharetta, Georgia, is a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals.

Forward Looking Statements

This press release contains “forward-looking statements,” within the meaning of the Private Securities Litigation Reform Act of 1995, regarding, among other things, the anticipated closing of, and proposed use of proceeds from, the private placement, Alimera’s commercial plans for ILUVIEN in Europe and the regulatory status of ILUVIEN in the United States. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual results to differ materially from those projected in its forward-looking statements. Meaningful factors which could cause actual results to differ include risks related to the satisfaction of the conditions to, and the timing of, the closing of the private placement, Alimera’s need for additional capital in the future, as well as other factors discussed in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of Alimera’s Annual Report on Form 10-K for the year ended December 31, 2012 and Quarterly Report on Form 10-Q for the quarter ended September 30, 2013, which are on file with the Securities and Exchange Commission (SEC) and available on the SEC’s website at www.sec.gov. In addition to the risks described above and in Alimera’s Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the SEC, other unknown or unpredictable factors also could affect Alimera’s results. There can be no assurance that the actual results or developments anticipated by Alimera will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Alimera. Therefore, no assurance can be given that the outcomes stated in such forward-looking statements and estimates will be achieved.

All forward-looking statements contained in this press release are expressly qualified by the cautionary statements contained or referred to herein. Alimera cautions investors not to rely too heavily on the forward-looking statements Alimera makes or that are made on its behalf. These forward-looking statements speak only as of the date of this press release (unless another date is indicated). Alimera undertakes no obligation, and specifically declines any obligation, to publicly update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.

For press inquiries: For investor inquiries:
Katie Brazel, FleishmanHillard  John Mills, ICR
for Alimera Sciences for Alimera Sciences
404-739-0150 310-954-1105
Katie.Brazel@fleishman.com John.Mills@ICRINC.com
Tuesday, January 28th, 2014 Uncategorized Comments Off on (ALIM) Announces $37.5 Million Private Placement

(IDIX) to Raise $106.7 Million Through Registered Direct Offering

CAMBRIDGE, Mass., Jan. 28, 2014  — Idenix Pharmaceuticals, Inc. (Nasdaq:IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced that it has entered into a definitive agreement with certain entities managed by The Baupost Group, L.L.C. (Baupost) for the sale of 16,420,241 shares of its common stock. Baupost has agreed to purchase the shares of common stock at a price of $6.50 per share, resulting in net proceeds to Idenix, after deducting estimated offering expenses, of approximately $106.7 million.

Baupost, which currently owns approximately 27% of the Company’s outstanding common stock, will beneficially own approximately 35% of the Company’s outstanding common stock upon completion of the offering. The sale and issuance of the shares is expected to close on or about January 31, 2014, subject to customary closing conditions. The proceeds of this offering will be used for general corporate purposes, including clinical trial costs and ongoing and future patent litigation expenses. The Company believes that its current cash and cash equivalents balance and the net proceeds from this offering will be sufficient to satisfy cash needs into at least the second half of 2015.

Pursuant to a letter of agreement between the parties, the Company has agreed that Baupost, for so as long as it holds at least 25% of the Company’s outstanding common stock, is entitled to observer rights with respect to meetings of the board of directors of the Company.

The securities described above are being offered directly to the purchasers by Idenix pursuant to a registration statement previously filed with and subsequently declared effective by the Securities and Exchange Commission (the “SEC”). This press release is not an offer to sell any of the securities described herein, and this press release is not an offer to buy these securities in any state where the offer or sale is not permitted. Copies of the prospectus supplement and accompanying base prospectus relating to this offering may be obtained by visiting EDGAR on the SEC’s website at www.sec.gov.

ABOUT IDENIX

Idenix Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts, is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases. Idenix’s current focus is on the treatment of patients with hepatitis C infection. For further information about Idenix, please refer to www.idenix.com.

FORWARD-LOOKING STATEMENTS

This press release contains “forward-looking statements” made under the provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements, other than statements of historical fact, regarding, without limitation, the completion, timing and size of the Company’s proposed offering and the use of proceeds therefrom. In some cases, words such as “will,” “expect” or other comparable words identify forward-looking statements. Actual results, performance or experience may differ materially from those expressed or implied by any forward-looking statement as a result of various important factors, including without limitation risks and uncertainties relating to the Company’s business and financial condition, general market conditions and the satisfaction of customary closing conditions associated with the proposed offering. Factors that may cause such a difference include, without limitation, risks and uncertainties related to whether or not the Company will be able to raise capital through the sale of shares of common stock, the final terms of the proposed offering, market and other conditions, the satisfaction of customary closing conditions related to the proposed offering and the impact of general economic, industry or political conditions in the United States or internationally. Risks and uncertainties that the Company faces are described in greater detail under the heading ” Risk Factors” in the Company’s annual report on Form 10-K for the year ended December 31, 2012 and the quarterly report on Form 10-Q for the quarter ended September 30, 2013, each as filed with the SEC and in any subsequent periodic or current report that the Company files with the SEC. As a result of the risks and uncertainties, the results or events indicated by any forward-looking statement may not occur. The Company cautions you not to place undue reliance on any forward-looking statement.

All forward-looking statements reflect the Company’s views only as of the date of this release and should not be relied upon as reflecting the Company’s views, expectations or beliefs at any date subsequent to the date of this release. While the Company may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so, even if the Company’s views, expectations or beliefs change.

CONTACT: Idenix Pharmaceuticals Contact:
         Teri Dahlman (617) 995-9807
Tuesday, January 28th, 2014 Uncategorized Comments Off on (IDIX) to Raise $106.7 Million Through Registered Direct Offering

(BGMD) Automated VIDAS(R) Galectin-3 Assay Validated in Published Clinical Research Study

WALTHAM, Mass., Jan. 28, 2014 — BG Medicine, Inc. (Nasdaq:BGMD), the developer of the BGM Galectin-3® Test, welcomed today the publication of results of a clinical research study that demonstrate and validate the analytical and clinical performance of the automated VIDAS® Galectin-3 assay that was developed by bioMérieux SA, a world leader in the field of in vitro diagnostics and one of BG Medicine’s automation partners.

In this clinical research study, published online ahead of print in the journal Clinica Chimica Acta, elevated galectin-3 levels in previously collected blood samples, measured using the VIDAS® Galectin-3 assay, were reported to be significantly predictive of fatal cardiovascular events and severity of heart failure among the 137 patients diagnosed with chronic heart failure who were tested.[1] The prognostic information provided by the VIDAS® Galectin-3 assay in this published clinical research study was found to be complementary and additive to that obtained by measurement of three different types of natriuretic peptides, including BNP, NT-proBNP and proBNP. The significant predictive value of galectin-3 levels was further demonstrated to be independent of other key clinical parameters, such as impaired kidney function, reduced cardiac left ventricular pumping capacity, and age. When evaluated for analytical performance, measurement values obtained with the VIDAS® Galectin-3 assay were found to be in excellent agreement with those obtained with the BGM Galectin-3® Test.

“We are very pleased with the results obtained with the automated VIDAS® Galectin-3 assay in this clinical research study,” said Dr. Paul R. Sohmer, President and CEO of BG Medicine, Inc. “These results support commercialization of the VIDAS® Galectin-3 assay in Europe and substantiate our efforts to assist bioMérieux with its pursuit of 510(k) clearance of the assay in the U.S.”

The VIDAS® Galectin-3 assay was developed by bioMérieux for the quantitative measurement of galectin-3 levels in blood using the bioMérieux VIDAS automated and multiparametric immunoassay testing system. The VIDAS® Galectin-3 assay requires 200 microliters of blood plasma or serum and is designed to return test results within 20 minutes. [2] This automated and quantitative assay for galectin-3 in blood is CE Marked and currently available in Europe as an aid in assessing the prognosis of patients diagnosed with chronic heart failure when used in conjunction with clinical evaluation.

[1] Gruson D, Mancini M, Ahn SA, Rousseau MF. Galectin-3 testing: Validity of a novel automated assay in heart failure patients with reduced ejection fraction, Clin Chim Acta (2013), http://dx.doi.org/10.1016/j.cca.2013.12.017.

[2] bioMérieux SA. (2014). VIDAS® Galectin-3. Retrieved from http://www.biomerieux-diagnostics.com/servlet/srt/bio/clinical-diagnostics/dynPage?open=CNL_CLN_PRD&doc=CNL_CLN_PRD_G_PRD_CLN_99&pubparams.sform=0&lang=en.

About Galectin-3 and Heart Failure

Galectin-3 has been implicated in a variety of biological processes important in the development and progression of heart failure. Higher levels of galectin-3 are associated with a more aggressive form of heart failure, which may make identification of high-risk patients using galectin-3 testing an important part of patient care. Galectin-3 testing may be useful in helping physicians determine which patients are at higher risk of death or hospitalization, including 30-day hospital readmission.

The BGM Galectin-3® Test quantitatively measures galectin-3 protein concentrations in blood serum and plasma. It is cleared by the U.S. FDA as an aid in assessing the prognosis of patients diagnosed with chronic heart failure when used in conjunction with clinical evaluation. The BGM Galectin-3 Test is also CE Marked and available in Europe as an aid in assessing the prognosis of patients diagnosed with acute and chronic heart failure when used in conjunction with clinical evaluation, and as an aid in assessing the risk of new onset heart failure in adults.

About BG Medicine, Inc.

BG Medicine, Inc. (Nasdaq:BGMD), the developer of the BGM Galectin-3® Test, is focused on the development and delivery of diagnostic solutions to aid in the clinical management of heart failure and related disorders. For additional information about BG Medicine, heart failure and galectin-3 testing, please visit www.BG-Medicine.com. The BG Medicine Inc. logo is available for download here.

Forward Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding: our belief that the results of the published clinical research study discussed herein support the commercialization of the bioMérieux VIDAS® Galectin-3 assay. These forward-looking statements are neither promises nor guarantees of future performance, and are subject to a variety of risks and uncertainties, many of which are beyond the Company’s control, which could cause actual results to differ materially from those contemplated in these forward-looking statements. These risks and uncertainties include, among other things, the factors discussed under the heading “Risk Factors” contained in BG Medicine’s annual report and quarterly reports filed with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and BG Medicine disclaims any obligation to update the information contained in this press release as new information becomes available.

CONTACT: Corporate Communications
         +1 (781) 890-1199
         BG Medicine, Inc.
Tuesday, January 28th, 2014 Uncategorized Comments Off on (BGMD) Automated VIDAS(R) Galectin-3 Assay Validated in Published Clinical Research Study